Table 2 Mean vildagliptin pharmacokinetic parameters (± SD) after the last administration of the test 1, test 2, and reference formulations
From: Bioequivalence study of different brands of vildagliptin in healthy human subjects
Parameter | Test 1 formulation | Test 2 formulation | Reference formulation |
|---|---|---|---|
Cmax (ng/ml) | 287.89 ± 3.51 | 287.41 ± 3.63 | 285.17 ± 5.01 |
Tmax (h) | 1.79 ± 0.26 | 1.79 ± 0.25 | 1.79 ± 0.27 |
AUC0-t (ng h/ml) | 1390.03 ± 23.81 | 1401.50 ± 30.70 | 1409.37 ± 30.29 |
AUC0-∞ (ng h/ml) | 1452.03 ± 32.97 | 1467.59 ± 38.06 | 1473.35 ± 32.97 |
t½ (h) | 2.59 ± 0.14 | 2.66 ± 0.16 | 2.63 ± 0.09 |
Kel (h−1) | 0.2678 ± 0.0160 | 0.2605 ± 0.0156 | 0.2617 ± 0.0096 |